Lichen Sclerosus (Investigational Adjunct)
Highly investigational adjunct for refractory lichen sclerosus; one small uncontrolled series (vulvar), no RCT; clobetasol remains standard of care.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for lichen sclerosus. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for lichen sclerosus is investigational.
- What evidence exists?
- Tier C (investigational). The only clinical report found is a small uncontrolled Russian series in vulvar disease; there are no randomized controlled trials. Evidence-based therapy for lichen sclerosus is ultra-potent topical corticosteroid (clobetasol propionate 0.05% once daily for 3 months, then maintenance) per AAD/BSGE guidelines. Topical calcineurin inhibitors as steroid-sparing. Vulvar disease requires gynecologic monitoring for squamous cell carcinoma risk (3-5 percent lifetime).
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Worsening of fragile lichen sclerosus skin with trauma
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Triggering of new lichen sclerosus lesions at bite sites (Koebner phenomenon)
- Scarring or distortion in fragile genital tissue
- Delay of clobetasol therapy and gynecologic SCC monitoring
- Risk of missed early squamous cell carcinoma in untreated disease
- Who should not consider this
- Patients with vulvar lichen sclerosus (gynecologic specialty care required)
- Patients with penile lichen sclerosus (urology referral)
- Patients with suspected squamous cell carcinoma (biopsy mandatory)
- Patients with active erosions, ulceration, or bleeding lesions
- Patients on anticoagulants, with hemophilia, or with anemia
- Patients who have not used clobetasol 0.05% consistently for 3 months
- What to ask your clinician
- Has the diagnosis been confirmed by biopsy?
- Have I been screened for squamous cell carcinoma risk?
- Have I used clobetasol propionate 0.05% as directed for 3 months?
- Am I being monitored by a gynecologist or urologist for genital disease?
- What evidence specifically supports leech therapy for lichen sclerosus?
- Are leeches from an FDA-registered supplier and used only once?
- What is the cost and is it covered by insurance? (typically not covered)
- When to seek urgent care
- New ulceration, persistent erosion, or new firm lump at any lichen sclerosus site (rule out SCC)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Severe genital pain, bleeding, or urinary obstruction
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for lichen sclerosus.
- A small uncontrolled series does NOT establish efficacy versus clobetasol 0.05%, the gold-standard treatment.
- It does NOT mean genital lichen sclerosus is appropriate for hirudotherapy — gynecologic or urologic specialty care is essential.
- It does NOT substitute for SCC screening — lichen sclerosus has a 3-5 percent lifetime SCC risk.
- It does NOT mean leech application is safe on fragile, atrophic, or eroded skin.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- L90.0
- Safety tier
- High
Evidence Summary
Lichen sclerosus is a chronic inflammatory dermatosis with sclerotic dermal change and a risk of squamous cell carcinoma in long-standing untreated disease. Standard of care per BAD and AAD guidance is an ultra-potent topical corticosteroid (clobetasol propionate 0.05%) with long-term maintenance, plus regular surveillance. No controlled clinical trial of leech therapy for lichen sclerosus was identified. The only clinical report found is an uncontrolled series of 12 women with biopsy-confirmed vulvar lichen sclerosus treated with leeches alongside their usual topical therapy and followed for 1 to 3 years (Khardikov 2021, Trudnyj Pacient, in Russian). All patients reported symptomatic improvement and repeat biopsies showed histological improvement, most marked in the 3 younger women, but the series had no comparison group and ran alongside continued topical steroids and hormones. It does not address extragenital plaques, which this entry is limited to, and no report of leech therapy for extragenital lichen sclerosus was identified. Direct anogenital application is contraindicated due to mucosal anatomy, infection risk, and lack of evidence. Patients must remain under dermatology follow-up for malignancy surveillance regardless of any adjunctive therapy. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Anogenital placement of any kind
- Active vulvar or penile intraepithelial neoplasia
- Suspected squamous cell carcinoma in any lichen sclerosus plaque
- Discontinuation of prescribed topical corticosteroid maintenance
Related Conditions
Cutaneous Lichen Planus (Localized)
Investigational use for localized cutaneous lichen planus refractory to topical corticosteroid; very limited case-report evidence.
Plaque Psoriasis (Localized)
Investigational adjunct, not a primary treatment; a few small, mostly uncontrolled studies report lower PASI scores.
Localized Scleroderma / Morphea (Investigational Adjunct)
Highly investigational adjunct for stable plaque morphea; no RCT evidence; UVA1 phototherapy and methotrexate remain primary for active disease.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.